Gainers
- Renovaro Biosciences (NASDAQ:RENB) shares increased by 292.9% to $3.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $212.7 million.
- Decibel Therapeutics (NASDAQ:DBTX) shares moved upwards by 75.26% to $4.89. The company's market cap stands at $122.3 million.
- Tango Therapeutics (NASDAQ:TNGX) shares rose 33.68% to $5.12. The market value of their outstanding shares is at $452.9 million. As per the news, the Q2 earnings report came out 2 days ago.
- 180 Life Sciences (NASDAQ:ATNF) shares increased by 32.24% to $1.02. The market value of their outstanding shares is at $5.4 million.
- Mirati Therapeutics (NASDAQ:MRTX) stock increased by 21.11% to $33.67. The company's market cap stands at $1.9 billion. The company's, Q2 earnings came out yesterday.
- Akanda (NASDAQ:AKAN) stock rose 19.35% to $0.72. The company's market cap stands at $2.8 million.
Losers
- Palisade Bio (NASDAQ:PALI) shares fell 66.1% to $0.66 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.4 million.
- Doximity (NYSE:DOCS) shares fell 23.0% to $25.25. The market value of their outstanding shares is at $4.9 billion. The company's, Q1 earnings came out yesterday.
- Vivos Therapeutics (NASDAQ:VVOS) stock declined by 18.11% to $0.33. The market value of their outstanding shares is at $9.8 million.
- Monopar Therapeutics (NASDAQ:MNPR) shares declined by 14.83% to $0.74. The company's market cap stands at $9.7 million.
- BioLife Solns (NASDAQ:BLFS) shares fell 13.0% to $16.0. The market value of their outstanding shares is at $695.7 million. As per the press release, Q2 earnings came out yesterday.
- Comera Life Sciences (NASDAQ:CMRA) stock fell 11.36% to $0.58. The market value of their outstanding shares is at $12.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
